Under the terms of the agreement, Sanofi will gain an exclusive right to first negotiation for the CNS-penetrant, VTX3232.
Sanofi invests $27 million in Ventyx Biosciences at $3.8243 per share. The investment will fund VTX3232 trials for ...
The Sanofi equity investment means the Big Pharma will receive exclusive rights of first negotiation surrounding VTX3232, an ...
“We are excited to initiate this trial of VTX3232 in patients with early Parkinson’s disease,” said Mark Forman, MD, PhD, Chief Medical Officer. “There is a compelling body of evidence ...
A Phase 2 obesity and cardiometabolic trial of VTX3232 and a Phase 2a trial of VTX3232 in patients with Parkinson’s disease are both expected to initiate in H2 2024 A Phase 2 trial ...
today announced that the first patient has been dosed in a Phase 2a trial of VTX3232 in patients with early Parkinson’s disease.
SAN DIEGO, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that ...
“We are excited to initiate this trial of VTX3232 in patients with early Parkinson’s disease,” said Mark Forman, MD, PhD, Chief Medical Officer. “There is a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback